hypercholesterolaemia
Cardiovascular · 2006–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| inclisiran Treatment of familial heterozygous hypercholesterolaemia (HeFH) and non-familial hypercholesterolaemia (non-FH) as an adjunct to diet and exercise to reduce… | Nov 2024 | Recommended with restriction | input received Heart Support Australia |
| evolocumab Treatment of hypercholesterolaemia in patients with inadequate control on statins, statin intolerance or contraindication, and established cardiovascular… | Mar 2015 | Not recommended | 15 individuals FH Family Support Group |
| ezetimibe + rosuvastatin Hypercholesterolaemia in patients with inadequate cholesterol control on statin monotherapy, in combination with dietary therapy and exercise. Indicated for… | Jul 2014 | Recommended with restriction | none received |
| ezetimibe + atorvastatin Hypercholesterolaemia in patients with inadequate cholesterol control on statin monotherapy, or homozygous familial hypercholesterolaemia. | Nov 2014 | Recommended with restriction | none received |
| ezetimibe + simvastatin Adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a… | Nov 2014 | Noted | none received |
| ezetimibe and atorvastatin Hypercholesterolaemia in combination with dietary therapy and exercise where cholesterol levels are inadequately controlled by atorvastatin in patients with… | Jul 2013 | Recommended | no section in document |
| ezetimibe and rosuvastatin Hypercholesterolaemia in patients with inadequately controlled cholesterol levels on statin monotherapy who have coronary heart disease, diabetes, peripheral… | Nov 2013 | Recommended with restriction | no section in document |
| ezetimibe with atorvastatin Treatment, in conjunction with dietary therapy and exercise, for co-administration of ezetimibe with atorvastatin in patients whose cholesterol levels are… | Jul 2012 | Recommended | unclear |
| ezetimibe with atorvastatin Treatment, in conjunction with dietary therapy and exercise, for co-administration of ezetimibe with atorvastatin in patients whose cholesterol levels are… | Jul 2012 | Recommended | unclear |
| ezetimibe and atorvastatin Treatment of patients whose cholesterol levels are inadequately controlled with a statin monotherapy, or patients with homozygous familial… | Nov 2012 | Recommended | unclear |
| sitagliptin with simvastatin Type 2 diabetes mellitus and hypercholesterolaemia in patients currently receiving simvastatin who satisfy criteria for DPP-4 inhibitor use. | Nov 2012 | Recommended with restriction | no section in document |
| ezetimibe and atorvastatin Treatment, in conjunction with dietary therapy and exercise, for co-administration of ezetimibe with atorvastatin in patients whose cholesterol levels are… | Nov 2012 | Recommended | unclear |
| ezetimibe Co-administration with a statin (rosuvastatin or atorvastatin) in patients with inadequate cholesterol control despite statin therapy, including those with… | Nov 2010 | Recommended with restriction | no section in document |
| rosuvastatin calcium Treatment of hypercholesterolaemia as an adjunct to diet when the response to diet and exercise is inadequate. | Jul 2006 | Recommended with restriction | no section in document |
Who spoke
FH Family Support Group · Heart Support Australia
What the PBS pays
$1,291M in government benefit over 2024–25, across 83,268,795 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ezetimibe + rosuvastatin | $195.4M |
| ezetimibe and rosuvastatin | $182.4M |
| ezetimibe + atorvastatin | $158.7M |
| ezetimibe and atorvastatin | $158.7M |
| ezetimibe with atorvastatin | $158.7M |
| rosuvastatin calcium | $132.6M |
| sitagliptin with simvastatin | $88.1M |
| ezetimibe + simvastatin | $65M |
| evolocumab | $63.2M |
| ezetimibe | $49.8M |
| inclisiran | $38.2M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| pravastatinAPO-PRAVASTATIN pravastatin sodium 10 mg tablets bottle | 1996 | 68 |
| fluvastatinLESCOL XL fluvastatin 80mg tablet blister pack | 2002 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.